Acquisition / mergerFiled on NSE ·

Q-Line Biotech Ltd reports H1 FY27 financials and IPO Fund Utilization as on 30.09.2026

Q-Line Biotech

Arthneeti Research DeskPublished 1 min read
₹122 CrAcquisition / merger

Key highlights

  • Board approved unaudited standalone and consolidated financial results for half year ended 30 September 2026, with limited review by auditors on 12 November 2026.
  • Monitoring Agency Report for IPO fund utilization up to 30 September 2026 issued by Care Ratings Limited, confirming utilization of ₹122.34 crore out of IPO proceeds of ₹214.48 crore; unutilized funds of ₹92.14 crore parked in fixed deposits with IndusInd Bank and HDFC Bank.
  • Board approved acquisition of 612,500 equity shares (70% paid-up capital) of Heidelco Medicore Private Limited, valued on Net Asset Value basis, a related party transaction under Section 188 of Companies Act.

Original filing

Outcome of Board Meeting

Read the filing on NSE (PDF) →

Companies guiding to strong growth

Ranked by management's own guidance on revenue and margins — not by us.

Rossell Techsys

Aerospace & Defense

Revenue growth 40%+Margin up 2%+

Sign up free to see all 6 →

See full rankings

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

More from Q-Line Biotech

Other acquisition / merger filings this fortnight

All acquisition / merger filings →

Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.